Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYD985 versus physician's choice in HER2-positive advanced or metastatic breast cancer
NL-OMON55876Phase 3Active, not recruiting
- Sponsor
- Byondis
- Start
- Sep 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab duocarmazine in breast cancer (2 arms), sponsored by Byondis. Primary endpoint: Progression-free survival. Started Sep 2018; status: active, not recruiting.
02
Drugs
trastuzumab duocarmazine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON55876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55876.